Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx ® Lung Signature

Conclusions Although numerous factors are considered when staging NSCLC, there remains a clinical unmet need to delineate risk of recurrence in early stage patients as stage alone does not fully elucidate which patients may benefit from adjuvant chemotherapy. Clinicopathological factors currently employed are not significantly associated with treatment effectiveness, with the exception of tumor size. GeneFx Lung is a robust gene signature that has been validated in several independent cohorts to estimate risk of recurrence in early stage NSCLC, with overall survival being significantly associated with GeneFx Lung risk category. The studies reviewed herein support use of GeneFx Lung to assess risk of recurrence in both adenocarcinoma and squamous cell carcinoma cases of early stage NSCLC, thereby facilitating adjuvant chemotherapy treatment decisions in these patients. Competing Interests SB and AU are paid employees of Helomics Corporation and hold stock options. These competing interests do not affect our adherence to the PLOS Currents policies on sharing data and materials.
Source: PLOS Currents Evidence on Genomic Tests - Category: Genetics & Stem Cells Authors: Source Type: research